INTRODUCTION
Telomerase is a ribonucleoprotein reverse transcriptase that directs the synthesis of telomeric repeats at chromosome ends [1] . Normal human somatic cells express low or undetectable telomerase activities and are mortal. In contrast, moderate or high telomerase activity is present in the majority of immortal and cancer cells [2, 3] . Ectopic expression of telomerase activity has been shown to extend the lifespan of several normal human cell types [4] [5] [6] [7] . Ectopic expression of the telomerase catalytic subunit (the reverse transcriptase subunit of human telomerase, hTERT) in combination with two other oncogenes (the simian virus 40 large-T oncoprotein and oncogenic allele of H-ras) has been shown to be sufficient to convert normal human epithelial and fibroblast cells into tumour cells [8] . Together these observations support an important role for telomerase in cellular immortalization and carcinogenesis.
The minimal catalytic core of human telomerase consists of an RNA component (hTER) and of a catalytic protein subunit (hTERT) with reverse transcriptase activity [9] [10] [11] [12] [13] [14] . Additional telomerase-associated proteins (hTEP1, dyskerin, p23 and Hsp90) have been identified [15] [16] [17] [18] , yet their biochemical functions remain obscure. Studies on the correlation between telomerase activity and the expression of hTER, hTEP1, and hTERT have indicated that telomerase activity is strongly correlated with the abundance of hTERT mRNA [10, 11] . The abundance of mRNA for hTEP1 and hTER does not correlate with telomerase activity [15, 16, 19] . Together with the result that ectopic expression of hTERT in somatic cells is sufficient to restore telomerase activity [4] [5] [6] [7] 12, 20 ], these observations demonstrate that hTERT is the key regulator of enzyme activity.
Abbreviations used : NPC, nasopharyngeal carcinoma ; PKC, protein kinase C ; BIM, bisindolylmaleimide I ; hTERT, reverse transcriptase subunit of human telomerase ; TRAP, telomeric-repeat-amplification protocol. 1 To whom correspondence should be addressed (e-mail tcvwg!mail.cgu.edu.tw).
the crude extracts of PKC-inhibited NPC cells. However, depletion of PKC-α and -βI in i o had no detectable effect on the telomerase activity of NPC cells. Using antisense oligonucleotides against individual PKC isotypes, we observed that telomerase activity was inhibited only by the antisense oligonucleotide against PKC-ζ but not by those against PKC-α, -βI or -δ. Taken together, these data demonstrate that PKC participates in the regulation of telomerase activity by direct or indirect phosphorylation of telomerase proteins, and that PKC-ζ is the PKC isotype that functions in i o in the NPC cells.
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Little is known concerning how telomerase activity is regulated in human cells. The promoter region of the hTERT gene has been characterized [21] [22] [23] . Sequence analysis has revealed that the hTERT promoter contains hormone-response elements and binding sites for several transcription factors, including c-Myc, Sp1 and others [21] [22] [23] , implying that hTERT expression may be regulated by multiple factors. Overproduction of c-Myc has been shown to induce expression of hTERT and of telomerase activity [24] [25] [26] , whereas inhibition of c-Myc inhibits telomerase activity in leukaemic cell lines [27] . Up-regulation of telomerase activity in T-lymphocytes during activation has been shown to correlate with the induction of hTERT expression [28] , and is known to require protein kinase C (PKC)-dependent activity [29, 30] . Similarly, down-regulation of telomerase activity in differentiated pro-myelocytic HL-60 cells has been shown to correlate with down-regulation of hTERT expression [11, 31] . Therefore, transcriptional regulation of hTERT expression appears to be the primary method of controlling telomerase. In addition to transcriptional regulation, reversible phosphorylation of telomerase proteins has been shown to control telomerase activity [32] [33] [34] . PKC-α is reported to be responsible for phosphorylating telomerase proteins in breast cancer cells [33] .
We have shown previously that the telomerase activity of human nasopharyngeal carcinoma (NPC) cells is inhibited by treatment with inhibitors of PKC, indicating that PKC is involved in the control of telomerase activity in these cells [35] . As yet, it is not known which PKC isotype is involved and what the mechanism of regulation by PKC in NPC cells is. In this study, we present evidence that PKC participates in the regulation of telomerase activity by direct or indirect phosphorylation of telomerase proteins, and that PKC-ζ is the PKC isotype that functions in the NPC cells in i o.
MATERIALS AND METHODS

Chemicals, enzymes, antibodies and oligonucleotides
Dulbecco's modified Eagle's medium, fetal bovine serum, LipofectAMINE TM 2000, Superscript II reverse transcriptase, TRIzol reagent and antibiotics were from Gibco-BRL. Bisindolylmaleimide I (BIM), RNase inhibitor and PMA were purchased from Calbiochem. PKC-α, -βI, -δ and -ζ were from BioMol Research Lab. Taq DNA polymerase was from Viogene (Taipei, Taiwan). Antibodies against individual PKC isotypes and secondary antibodies were from Santa Cruz Biotechnology. Anti-digoxigenin antibody conjugated with horseradish peroxidase was from Boehringer Mannheim. The sequences and sources of oligonucleotides TS, CX, biotinylated TS and digoxigeninated CX have been described previously [36] . Other oligonucleotides used are listed in Table 1 and were from Genasia Scientifics (Taipei, Taiwan). The antisense oligonucleotides against PKC-α, -βI, -δ and -ζ were synthesized as phosphorothiotide derivatives and tagged at the 5h ends with FITC. Gelelectrophoresis reagents were from BioRad. All other chemicals were from Sigma.
Cell culture
NPC-derived cell line NPC-076 was cultured routinely in Dulbecco's modified Eagle's medium supplemented with 10 % fetal bovine serum, 2 mM -glutamine, 100 units\ml penicillin, 100 units\ml streptomycin and 0.25 µg\ml amphotericin B. Cells were grown at 37 mC in a humidified incubator containing 5 % CO # .
Telomerase activity assay
Cell extracts were obtained as described in [35] . Telomerase activity was assayed by conventional telomeric-repeatamplification protocol (TRAP) [2] and by a PCR-based enzyme immunoassay as described previously [36] .
Determination of mRNA expression of hTERT by reverse transcriptase PCR
Total RNA was extracted by TRIzol isolation reagent (Gibco-BRL) following the manufacturer's instructions. The primers used were : LT5 and LT6 for hTERT [11] and K136 and K137 for GAPDH [11] (see Table 1 ). The conditions for reverse transcriptase PCR were predetermined with serial dilutions of total RNA isolated from the untreated NPC-076 cells such that the amount of RNA used in the reaction was in the linear range Table 1 Sequences of the oligonucleotides used 
Figure 3 Reactivation of telomerase activity by in vitro phosphorylation of PKC-inhibited cell extract
Cell extracts were obtained from NPC-076 cells treated with 10 µM BIM for 3 days and were phosophorylated in vitro by exogenous addition of PKC-α (A), -βI (B), -δ (C) or -ζ (D) as described in the Materials and methods section. Aliquots of phosphorylated cell extract (0.5 µg) were assayed for telomerase activity using PCR-based enzyme immunoassay. C is a control using NPC-076 cell extract not treated with BIM. E means reaction with BIM-treated cell extract. Results are the means from two experiments.
of the assay. In brief, reverse transcription was performed at 42 mC for 1 h in 20 µl of buffer containing 50 mM Tris (pH 8.3), 75 mM KCl, 3 mM MgCl # , 2 µg of total RNA, 0.5 µg of oligodT, 10 units of RNasin, 4 units of Superscript II and dNTPs at 1 mM. Reverse transcriptase reaction products (2 µl) were added to 20 µl of PCR mixture containing 20 mM Tris (pH 8.3), 50 mM KCl, 0.25 mM dNTPs, 0.1 mg\ml BSA, 0.5 mM MgCl # , 10 pmol of each primer and 2 units of Taq DNA polymerase. PCR amplification for cDNA of hTERT and GAPDH was carried out with 31 cycles of denaturation at 94 mC for 30 s, annealing at 55 mC for 30 s, and extension at 72 mC for 1 min. The PCR products were resolved by electrophoresis on a 2.5 % agarose gel and analysed as described in [35] .
Western-blot analysis of PKC isotypes
Western-blot analysis was performed as follows. Protein extract (20 µg) was added to a sample buffer containing 25 mM Tris\ HCl (pH 6.8), 5 % glycerol, 1 % SDS, 0.1 M dithiothreitol and 0.1 % Bromophenol Blue, and boiled for 5 min. After electrophoresis in an SDS\polyacrylamide gel (8 %), proteins were transferred to a PVDF membrane in a wet transfer system (Hoefer Pharmacia Biotech) at 0.8 mA\cm# for 2 h using a buffer containing 10 mM Caps and 20 % methanol. The membrane was then blocked by immersing in TTBS buffer [10 mM Tris\HCl (pH 8.3), 0.05 % Tween-20 and 150 mM NaCl] containing 5 % non-fat dried milk at 4 mC overnight. After decanting the blocking buffer, membrane was incubated with anti-PKC antibody in TTBS buffer for 2 h at room temperature. After washing four times with TTBS, membrane was incubated with horseradish peroxidase in TTBS for 1 h at room temperature. After washing, membrane was submerged in ECL developing solution (Amersham Pharmacia Biotech, Little Chalfont, Bucks., U.K.) and autoradiographed. The level of actin was used as an internal control to determine the relative expression of PKC isotypes in different samples.
Transfection of oligonucleotides
Antisense oligonucleotides against PKC-α, -βI, -δ or -ζ were transfected into NPC-076 cells using LipofectAMINE TM 2000 following the supplier's instructions.
Protein phosphorylation in vitro
The conditions for protein phosphorylation followed those described by Li et al. [33] . For PKC-mediated protein phosphorylation, 5 µg of protein extract was phosphorylated by exogenous addition of individual PKC isotypes to a 20 µl reaction mixture containing 30 mM Tris\HCl (pH 7.4), 1 mM MgCl # , 1 mM EGTA, 0.2 mM CaCl # , 10 µM PMA, 40 µg\ml phosphatidylserine and 40 µM ATP. After incubation at 30 mC for 15 min, aliquots of phosphorylated cell extract were assayed for telomerase activity as described above.
RESULTS AND DISCUSSION
Inhibition of PKC activity has been shown to inhibit telomerase activity of NPC cells [35] . Since PKC can control telomerase activity by regulating the expression of telomerase genes and\or by phosphorylating telomerase proteins, the first question we addressed was whether the expression of the key telomerase regulator, hTERT, is suppressed by inhibiting PKC. NPC-076 cells were treated with BIM, an inhibitor of PKC, and the expression of hTERT mRNA and telomerase activity were followed. As shown in Figure 1 , telomerase activity of NPC-076 cells was inhibited by BIM in a dose-dependent and timedependent manner, as observed before [35] . However, the expression hTERT mRNA was not inhibited at all (Figure 2 ). This result indicates that the inhibition of telomerase activity by BIM is not due to the suppression of hTERT expression.
Inhibition of telomerase activity by BIM without downregulating hTERT expression suggests that PKC may control telomerase activity by phosphorylating telomerase proteins in NPC cells. Accordingly, we postulate that the telomerase of BIM-treated cells is not phosphorylated and, therefore, lacks activity. Rephosphorylation of telomerase in BIM-treated cells should lead to the activation of telomerase activity. To test this postulate, cell extracts were prepared from NPC-076 cells that had been pretreated with 10 µg\ml BIM for 3 days. These cell extracts were phosphorylated in itro by exogenous addition of PKC isotypes that were expressed in NPC-076 cells, and tested for the restoration of telomerase activity. As shown in Figure 3 , phosphorylation of BIM-treated cell extracts by exogenous addition of any individual PKC, α, βI, δ or ζ, led to restoration of telomerase activity. Therefore, the inhibition of telomerase activity observed in BIM-treated cells (Figure 1 ) is probably attributable to the lack of phosphorylation in the telomerase proteins.
Although any one of PKC-α, -δ, -ε or -ζ has been shown to be capable of restoring telomerase activity in protein phosphatase 2A-treated nuclear extracts of breast cancer cells in itro, only PKC-α is thought to be responsible for the in i o phosphorylation of telomerase proteins [33] . Therefore, despite the fact that any one of PKC-α, -βI, -δ or -ζ can restore telomerase activity of PKC-inhibited cell extracts in itro ( Figure  3 ), NPC cells may employ only one PKC isotype to control telomerase activity in i o. An obvious question to be addressed is whether NPC-076 cells might employ PKC-α to control telomerase activity. An antisense oligonucleotide against PKC-α was used to specifically inhibit PKC-α, and was found to produce little or no inhibition of telomerase activity ( Figure 4A ). Under our experimental conditions, more than 75 % of the cells were transfected effectively with the FITC-tagged oligonucleotides, as seen from microscopic examination of cells that display fluorescence. Western-blot analysis revealed that the level of PKC-α in the antisense-PKC-α-treated cells was reduced to about 20 % of the untreated control after 3 days ( Figure 5 ). The lack of telomerase inhibition by antisense-PKC-α, therefore, suggests that either PKC-α does not control telomerase activity in NPC cells or that the residual PKC-α in the treated cells is sufficient to control telomerase activity. To address this problem, we investigated the effect of depleting PKC-α on the telomerase activity. NPC-076 cells were treated with 100-200 ng\ml PMA, an agent known to deplete PKC-α and down-regulate PKC upon prolonged treatment [37] , and the levels of telomerase activity and PKC isotypes were analysed. As shown in Figure 6 , there was no detectable inhibition of telomerase activity during the entire treatment period. Western-blot analysis revealed that PKC-α and PKC-βI were depleted rapidly from the cells treated with PMA and were not detectable after 24 h (Figure 7 ). PKC-δ was also depleted from the cells, but at a much slower rate. In contrast, there was little change in the levels of PKC-ζ during the entire treatment period. Since PKC-α and PKC-βI were depleted to undetectable levels in the PMA-treated cells, yet the telomerase activity was not inhibited at all, these results demonstrate that PKC-α and PKC-βI do not regulate the basal activity of telomerase in NPC-076 cells.
To determine whether PKC-δ or PKC-ζ might be involved in the control of telomerase activity and to confirm that PKC-βI does not control telomerase activity, NPC-076 cells were treated with antisense oligonucleotides against PKC-βI, PKC-δ or PKC-ζ, and the levels of PKC isotypes and telomerase activity were examined. Whereas the levels of the three PKC isotypes were greatly reduced by the antisense oligonucleotides ( Figure 5 ), treatment of NPC-076 cells with antisense-PKC-βI or antisense-PKC-δ did not inhibit telomerase in the first 2 days and only slightly reduced telomerase activity by day 3 ( Figures 4B and  4D ). In contrast, the telomerase activity of cells treated with antisense-PKC-ζ was inhibited significantly, beginning at day 2, and was reduced to less than 25 % of the untreated control after 3 days ( Figure 4C ). Transfection of sense PKC-ζ oligonucleotides produced no inhibition of telomerase activity (results not shown), and the results were similar to that produced by antisense-PKC-α, antisense-PKC-βI or antisense-PKC-δ. The specific inhibition of telomerase activity by antisense-PKC-ζ indicates that PKC-ζ controls telomerase activity in NPC cells. This conclusion is also consistent with the results shown for PMA-treated cells ( Figures  6 and 7) in that the lack of PKC-ζ degradation was accompanied by a lack of telomerase inhibition.
Taken together, these results establish that PKC participates in the regulation of telomerase activity in NPC cells by direct or indirect phosphorylation of telomerase proteins and not by PKC-dependent signal transduction to regulate the expression of the key telomerase component, hTERT. Of the four PKC isotypes expressed in NPC cells, we provide evidence that PKC-ζ is the PKC isotype that controls telomerase in i o. Our findings are consistent with idea that reversible phosphorylation of telomerase proteins plays an important role in regulating telomerase activity in cancer cells [32] [33] [34] 38] . However, our finding of a pivotal role of PKC-ζ in the control of telomerase in i o differs from that reported for PKC-α in human breast cancer cells [33] . This difference may be due to experimental methods and\or different types of cancer cells used. Evidence for a specific regulatory role of PKC-α in human breast cancer cells is based on the association of PKC-α with partially purified telomerase in the nuclei of such cells [33] . Our deduction for a regulatory role of PKC-ζ, but not PKC-α or other PKC isotypes, is based on studies with antisense oligonucleotides against individual PKC isotypes and with a PKC-down-regulating agent, PMA (Figures  4-6 ). It is likely that the conclusions drawn from both studies are valid, the difference may merely reflect that different PKC isotypes are used in different types of cell to regulate telomerase.
